c2.KYNG ENVIRONMENTAL STRESS RESPONSE NOT BY GAMMA IN WS c2.REACTOME MATURATION OF TCA ENZYMES AND REGULATION OF TCA CYCLE c2.PLASARI TGFB1 SIGNALING VIA NFIC 1HR DN c2.KEGG PROSTATE CANCER c2.REACTOME INTRA GOLGI TRAFFIC c2.REACTOME MALATE ASPARTATE SHUTTLE c2.WESTON VEGFA TARGETS 12HR c2.PICCALUGA ANGIOIMMUNOBLASTIC LYMPHOMA UP c2.NICK RESPONSE TO PROC TREATMENT UP c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED CACNA1D H TO ANGIOTENSIN ALDOSTERONE SIGNALING PATHWAY	erve sheath tumo	rle and epithelioid t	Gliomas	Flioneuronal tumor	
c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED KCNJ5 TO ANGIOTENSIN ALDOSTERONE SIGNALING PATHWAY c2.KANG AR TARGETS DN c2.KEGG ADHERENS JUNCTION c2.REACTOME GLYCOGEN SYNTHESIS c2.REACTOME INSULIN PROCESSING c2.BYSTRYKH HEMATOPOIESIS STEM CELL QTL CIS c2.HU GENOTOXIC DAMAGE 24HR c2.TORCHIA TARGETS OF EWSR1 FLI1 FUSION TOP20 DN c2.WP HEAD AND NECK SQUAMOUS CELL CARCINOMA c2.KEGG THYROID CANCER c2.SCHEIDEREIT IKK TARGETS c2.PID CMYB PATHWAY c2.REACTOME INTRINSIC PATHWAY FOR APOPTOSIS c2.REACTOME CHROMATIN MODIFICATIONS DURING THE MATERNAL TO ZYGOTIC TRANSITION MZT c2.KEGG MEDICUS REFERENCE TRANSCRIPTIONAL ACTIVATION BY ACETYLATION OF H3K27 c2.REACTOME CONSTITUTIVE SIGNALING BY AKT1 E17K IN CANCER					
C2.BIOCARTA NKCELLS PATHWAY C2.KEGG MEDICUS PATHOGEN HCMV US28 TO GNB G PI3K NFKB SIGNALING PATHWAY C2.PID IL8 CXCR1 PATHWAY C2.PID IL2 PI3K PATHWAY C2.PID IL2 PI3K PATHWAY C2.PID IL2 PI3K PATHWAY C2.PID IL2 PI3K PATHWAY C2.BENPORATH MYC MAX TARGETS C2.EENPORATH MYC MAX TARGETS C2.KEGG MEDICUS REFERENCE EGF EGFR PLCG CALCINEURIN SIGNALING PATHWAY C2.GRANDVAUX IRF3 TARGETS DN C2.CGRANDVAUX IRF3 TARGETS DN C2.CONTON AND PARVB TARGETS DN C2.CONTON AND PARVB TARGETS 2 DN C2.CONTON PARVB TARGETS C2.CONTON					
c2.UNTERMAN IPF VS CTRL DC UP c2.KEGG TIGHT JUNCTION c2.LEE AGING MUSCLE DN c2.HOLLERN ADENOMYOEPITHELIAL BREAST TUMOR c2.PID CDC42 REG PATHWAY c2.SABATES COLORECTAL ADENOMA SIZE UP c2.KEGG MEDICUS REFERENCE COHESIN DISSOCIATION IN PROPHASE c2.NABA MATRISOME HGSOC OMENTAL METASTASIS c2.GROSS HIF1A TARGETS DN c2.WP EXTRACELLULAR VESICLEMEDIATED SIGNALING IN RECIPIENT CELLS c2.JIANG HYPOXIA CANCER c2.KEGG MEDICUS REFERENCE TGF BETA SIGNALING PATHWAY c2.BIOCARTA RNAPOL3 PATHWAY c2.MEBARKI HCC PROGENITOR WNT UP CTNNB1 INDEPENDENT c2.REACTOME TRANSCRIPTIONAL REGULATION BY NPAS4 c2.REACTOME SIGNALING BY RHO GTPASES MID GTPASES AND RHOBTB3 c2.BIOCARTA TEL PATHWAY c2.BHATTACHARYA EMBRYONIC STEM CELL					
C2.KEGG MEDICUS PATHOGEN KSHV K15 TO TNF NFKB SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE ANGIOTENSIN ALDOSTERONE SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE ANGIOTENSIN ALDOSTERONE SIGNALING PATHWAY C2.WINSULIN SIGNALING C2.REACTOME ACTIVATION OF NMDA RECEPTORS AND POSTSYNAPTIC EVENTS C2.KEGG MEDICUS VARIANT EGFR OVEREXPRESSION TO PI3K SIGNALING PATHWAY C2.PID SYNDECAN 4 PATHWAY C2.REACTOME REGULATED PROTEOLYSIS OF P75NTR C2.REACTOME REGULATED PROTEOLYSIS OF P75NTR C2.REACTOME PECAM1 INTERACTIONS C2.DACOSTA UV RESPONSE VIA ERCC3 XPCS DN C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO RETROGRADE AXONAL TRANSPORT C2.WP PHOTODYNAMIC THERAPYINDUCED UNFOLDED PROTEIN RESPONSE C2.SENESE HDAC3 TARGETS UP C2.GROSS HYPOXIA VIA ELK3 AND HIF1A DN C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABBERANT ATXN2 3 TO MGLURES CA2 APOPTOTIC PATHWAY C2.REACTOME RETROGRADE TRANSPORT AT THE TRANS GOLGI NETWORK C2.WP MECHANOREGULATION AND PATHOLOGY OF YAPTAZ VIA HIPPO AND NONHIPPO MECHANISMS C2.REACTOME ANINO ACIDS REGULATE MTORC1					
C2.REACTOME RNA POLYMERASE III TRANSCRIPTION TERMINATION C2.WP MELATONIN METABOLISM AND EFFECTS C2.KEGG MEDICUS PATHOGEN HIV GP120 TO CXCR4 GNAQ PLCB G CALCINEURIN C2.REACTOME SIGNALING BY NOTCH1 C2.REACTOME INTERLEUKIN 1 FAMILY SIGNALING C2.BIOCARTA CK1 PATHWAY C2.REACTOME LINOLEIC ACID LA METABOLISM C2.MITSIADES RESPONSE TO APLIDIN DN C2.CHEN HOXAS TARGETS 9HR DN C2.FERNANDEZ BOUND BY MYC C2.WP TYPE I COLLAGEN SYNTHESIS IN THE CONTEXT OF OSTEOGENESIS IMPERFECTA C2.REACTOME FORMATION OF INCISION COMPLEX IN GG NER C2.DING LUNG CANCER MUTATED RECURRENTLY C2.PID MAPK TRK PATHWAY C2.REACTOME ANTIVIRAL MECHANISM BY IFN STIMULATED GENES C2.REACTOME PRE NOTCH EXPRESSION AND PROCESSING C2.WENG POR TARGETS GLOBAL UP C2.QI PLASMACYTOMA DN					
C2.CHICAS RB1 TARGETS LOW SERUM C2.BOHN PRIMARY IMMUNODEFICIENCY SYNDROM UP C2.NAISHIRO CTNNB1 TARGETS WITH LEF1 MOTIF C2.DOANE BREAST CANCER CLASSES DN C2.BIOCARTA FBW7 PATHWAY C2.KEGG MEDICUS VARIANT AMPLIFIED MET TO PI3K SIGNALING PATHWAY C2.REACTOME RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF KERATINOCYTES C2.KEGG GNRH SIGNALING PATHWAY C2.WP IL4 SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE CXCR4 GNB G RAC SIGNALING PATHWAY C2.REACTOME RSK ACTIVATION C2.WP EPAC1 AND PKA REDUCTION OF RETINAL INFLAMMATION C2.MILI PSEUDOPODIA HAPTOTAXIS DN C2.KEGG MEDICUS VARIANT TGFA OVEREXPRESSION TO PI3K SIGNALING PATHWAY C2.WP LIVER X RECEPTOR PATHWAY C2.WP LIVER X RECEPTOR PATHWAY C2.REACTOME NADE MODULATES DEATH SIGNALLING					
c2.REACTOME REGULATION OF CHOLESTEROL BIOSYNTHESIS BY SREBP SREBF c2.CHOW RASSF1 TARGETS UP c2.REACTOME SERINE BIOSYNTHESIS c2.REACTOME SYNTHESIS OF GDP MANNOSE c2.BYSTRYKH HEMATOPOIESIS STEM CELL IL3RA c2.STRYKH HEMATOPOIESIS STEM CELL IL3RA c2.LEE LIVER CANCER DENA UP c2.LEE LIVER CANCER DENA UP c2.LEE LIVER CANCER DENA UP c2.REACTOME FORMATION OF ATP BY CHEMIOSMOTIC COUPLING c2.WAKABAYASHI ADIPOGENESIS PPARG RXRA BOUND WITH H4K20ME1 MARK c2.POMEROY MEDULLOBLASTOMA PROGNOSIS UP c2.JIANG HYPOXIA NORMAL c2.BILANGES SERUM SENSITIVE GENES c2.KYNG WERNER SYNDROM DN c2.KEGG MEDICUS REFERENCE GNRH GNRHR PLCB PKC SIGNALING PATHWAY c2.REACTOME NFE2L2 REGULATING ANTI OXIDANT DETOXIFICATION ENZYMES c2.KEGG MEDICUS REFERENCE MDM2 P21 CELL CYCLE G1 S N00066					
c2.KEGG MEDICUS VARIANT AMPLIFIED MDM2 TO P21 CELL CYCLE G1 S c2.BRACHAT RESPONSE TO METHOTREXATE UP c2.RAMALHO STEMNESS UP c2.PID SYNDECAN 1 PATHWAY c2.MCCABE HOX.66 TARGETS UP c2.THUM MIR21 TARGETS HEART DISEASE UP c2.SASAI RESISTANCE TO NEOPLASTIC TRANSFROMATION c2.REACTOME RUNX1 REGULATES GENES INVOLVED IN MEGAKARYOCYTE DIFFERENTIATION AND PLATELET FUNCTION c2.REACTOME METABOLISM OF AMINO ACIDS AND DERIVATIVES c2.BIOCARTA NTHI PATHWAY c2.WP 5Q35 COPY NUMBER VARIATION c2.ALFANO MYC TARGETS c2.XU RESPONSE TO TRETINOIN DN c2.REACTOME TNFR2 NON CANONICAL NF KB PATHWAY c2.SANCHEZ MDM2 TARGETS c2.SANCHEZ MDM2 TARGETS c2.REACTOME METALLOPROTEASE DUBS c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SOD1 TO INTRINSIC APOPTOTIC PATHWAY c2.PAPASPYRIDONOS UNSTABLE ATTEROSCLEROTIC PLAQUE UP					
c2.SHAFFER IRF4 TARGETS IN ACTIVATED B LYMPHOCYTE c2.PID A6B1 A6B4 INTEGRIN PATHWAY c2.KEGG PROXIMAL TUBULE BICARBONATE RECLAMATION c2.TURJANSKI MAPK11 TARGETS c2.BURTON ADIPOGENESIS PEAK AT OHR c2.REACTOME DEACTIVATION OF THE BETA CATENIN TRANSACTIVATING COMPLEX c2.NABA MATRISOME PRIMARY METASTATIC COLORECTAL TUMOR c2.WP REGULATION OF ACTIN CYTOSKELETON c2.PID PI3KCI PATHWAY c2.BIOCARTA MHC PATHWAY c2.KEGG INSULIN SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE RETROGRADE AXONAL TRANSPORT c2.BARIS THYROID CANCER DN c2.KEGG CIRCADIAN RHYTHM MAMMAL c2.VALK AML CLUSTER 15 c2.REACTOME P75NTR REGULATES AXONOGENESIS c2.WP ROBO4 AND VEGF SIGNALING CROSSTALK c2.RUAN RESPONSE TO TNF TROGLITAZONE UP					
C2.CUI TCF21 TARGETS UP C2.TIEN INTESTINE PROBIOTICS 2HR DN C2.NABA MATRISOME POORLY METASTATIC MELANOMA TUMOR CELL DERIVED C2.KEGG ENDOCYTOSIS C2.MYLLYKANGAS AMPLIFICATION HOT SPOT 15 C2.MYLLYKANGAS AMPLIFICATION HOT SPOT 15 C2.MAINA VHL TARGETS UP C2.REACTOME NEGATIVE REGULATORS OF DDX58 IFIH1 SIGNALING C2.HOLLEMAN ASPARAGINASE RESISTANCE ALL DN C2.WANG LMO4 TARGETS UP C2.REACTOME SYNTHESIS OF DNA C2.BIOCARTA SHH PATHWAY C2.KYNG DNA DAMAGE BY 4NQO C2.PID MYC PATHWAY C2.CAFFAREL RESPONSE TO THC 24HR 5 DN C2.REACTOME DOWNSTREAM SIGNALING OF ACTIVATED FGFR4 C2.PID WNT NONCANONICAL PATHWAY C2.POMEROY MEDULLOBLASTOMA DESMOPLASIC VS CLASSIC UP C2.REACTOME S PHASE					
c2.REACTOME REPLACEMENT OF PROTAMINES BY NUCLEOSOMES IN THE MALE PRONUCLEUS c2.REACTOME NR1H2 AND NR1H3 MEDIATED SIGNALING c2.LEE AGING CEREBELLUM UP c2.MCBRYAN PUBERTAL BREAST 3 4WK DN c2.DESERT EXTRACELLULAR MATRIX HEPATOCELLULAR CARCINOMA SUBCLASS UP c2.KEGG PANCREATIC CANCER c2.ZHENG FOXP3 TARGETS DN c2.YH RESPONSE TO ARSENITE C4 c2.REACTOME INTEGRIN SIGNALING c2.HEBERT MATRISOME TNBC BONE BRAIN LIVER LUNG METASTASTASES c2.MARIADASON RESPONSE TO BUTYRATE SULINDAC 6 c2.KEGG MEDICUS VARIANT DELETED DMD TO DYSTROPHIN ASSOCIATED PROTEIN COMPLEX c2.MARIATA VIRULENCE OF H PILORI c2.DANG BOUND BY MYC c2.REACTOME DISEASES OF MITOTIC CELL CYCLE c2.APPEL IMATINIB RESPONSE c2.WP NANOPARTICLE TRIGGERED AUTOPHAGIC CELL DEATH c2.BIOCARTA CARDIACEGF PATHWAY c2.LOPEZ MESOTHELIOMA SURVIVAL DN					
C2.REACTOME NUCLEAR EVENTS STIMULATED BY ALK SIGNALING IN CANCER C2.SCHAEFFER PROSTATE DEVELOPMENT 12HR DN C2.REACTOME MITOTIC PROPHASE C2.WP CHROMOSOMAL AND MICROSATELLITE INSTABILITY IN COLORECTAL CANCER C2.HOWLIN CITED1 TARGETS 1 UP C2.WU HBX TARGETS 2 DN C2.KIM WT1 TARGETS 12HR UP C2.LAIHO COLORECTAL CANCER SERRATED DN C2.CAFFAREL RESPONSE TO THC 8HR 5 DN C2.REACTOME NEUTROPHIL DEGRANULATION C2.WACKER HYPOXIA TARGETS OF VHL C2.REACTOME DOWNSTREAM SIGNALING OF ACTIVATED FGFR3 C2.HOLLEMAN VINCRISTINE RESISTANCE ALL UP C2.KONDO HYPOXIA C2.MARSHALL VIRAL INFECTION RESPONSE UP C2.ANASTASSIOU MULTICANCER INVASIVENSES SIGNATURE C2.REACTOME DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN METABOLISM C2.REGORY SYNTHETIC LETHAL WITH IMATINIB					
c2.REACTOME RAC2 GTPASE CYCLE c2.REACTOME REGULATION OF NPAS4 MRNA TRANSLATION c2.JOSEPH RESPONSE TO SODIUM BUTYRATE DN c2.THUM SYSTOLIC HEART FAILURE UP c2.DAZARD UV RESPONSE CLUSTER G6 c2.DUNNE TARGETS OF AMLI MTG8 FUSION DN c2.BIDUS METASTASIS UP c2.REACTOME DNA DOUBLE STRAND BREAK RESPONSE c2.WP AMINO ACID METABOLISM IN TRIPLENEGATIVE BREAST CANCER CELLS c2.REACTOME DAG AND IP3 SIGNALING c2.BIOCARTA CFTR PATHWAY c2.WP VITAMIN D IN INFLAMMATORY DISEASES c2.SCHMAHL PDGF SIGNALING c2.HE PTEN TARGETS UP c2.REACTOME NOTCH HLH TRANSCRIPTION PATHWAY c2.WP FACTORS AND PATHWAYS AFFECTING INSULINLIKE GROWTH FACTOR IGF1AKT SIGNALING c2.REACTOME SIGNALING BY RECEPTOR TYROSINE KINASES c2.REACTOME SIGNALING BY RECEPTOR TYROSINE KINASES c2.REACTOME PHOSPHOLIPIDS PURPLE DN					
C2.REACTOME RAB GEFS EXCHANGE GTP FOR GDP ON RABS C2.RP 7Q1123 COPY NUMBER VARIATION SYNDROME C2.WP ALZHEIMERS DISEASE AND MIRNA EFFECTS C2.WP ALZHEIMERS DISEASE AND MIRNA EFFECTS C2.BIOCARTA TID PATHWAY C2.WP OSTEOARTHRITIC CHONDROCYTE HYPERTROPHY C2.UNTERMAN PROGRESSIVE VS STABLE IPF CD8T DN C2.REACTOME SYNTHESIS OF PYROPHOSPHATES IN THE CYTOSOL C2.REACTOME REGULATION OF MITF M DEPENDENT GENES INVOLVED IN APOPTOSIS C2.BIOCARTA PPARG PATHWAY C2.REACTOME REGULATION OF MITF M DEPENDENT GENES INVOLVED IN APOPTOSIS C2.BIOCARTA PPARG PATHWAY C2.REACTOME VITAMIN C ASCORBATE METABOLISM C2.CONRAD GERMLINE STEM CELL C2.KEGG BIOSYNTHESIS OF UNSATURATED FATTY ACIDS C2.WP NPHP1 DELETION SYNDROME C2.KYNG RESPONSE TO H2O2 VIA ERCC6 UP C2.REACTOME ADORA2B MEDIATED ANTI INFLAMMATORY CYTOKINES PRODUCTION C2.DARWICHE PAPILLOMA RISK LOW UP					
c2.PID NFKAPPAB ATYPICAL PATHWAY c2.ROZANOV MMP14 CORRELATED c2.HARRIS HYPOXIA c2.TOOKER GEMCITABINE RESISTANCE UP c2.REACTOME KINESINS c2.KEGG MEDICUS REFERENCE VALINE DEGRADATION c2.PID INTEGRINS PATHWAY c2.JIANG VHL TARGETS c2.GROSS HYPOXIA VIA ELK3 ONLY DN c2.WAMUNYOKOLI OVARIAN CANCER LMP DN c2.REACTOME SIGNALING BY MAPK MUTANTS c2.BIOCARTA ACTINY PATHWAY c2.ROY WOUND BLOOD VESSEL UP c2.YAMANAKA GLIOBLASTOMA SURVIVAL UP c2.REACTOME THROMBIN SIGNALLING THROUGH PROTEINASE ACTIVATED RECEPTORS PARS c2.KEGG MEDICUS PATHOGEN EBY LMP1 TO NFKB SIGNALING BY MAPK c2.CHIANG LIVER CANCER SUBCLASS UNANNOTATED DN					
c2.PETRETTO BLOOD PRESSURE DN c2.GAJATE RESPONSE TO TRABECTEDIN UP c2.GUENTHER GROWTH SPHERICAL VS ADHERENT UP c2.RODRIGUES DCC TARGETS DN c2.REACTOME P75NTR NEGATIVELY REGULATES CELL CYCLE VIA SC1 c2.WP INTERLEUKIN1 IL1 STRUCTURAL PATHWAY c2.REACTOME RET SIGNALING c2.BIOCARTA VITCB PATHWAY c2.KEGG ALDOSTERONE REGULATED SODIUM REABSORPTION c2.PID KIT PATHWAY c2.REACTOME GAP JUNCTION ASSEMBLY c2.REACTOME PKA MEDIATED PHOSPHORYLATION OF CREB c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 12 c2.REACTOME FRET MUTANT RECEPTOR ACTIVATION c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO MGLUR5 CA2 APOPTOTIC PATHWAY c2.WP SPHINGOLIPID PATHWAY c2.WP SPHINGOLIPID PATHWAY c2.REACTOME FOXO MEDIATED TRANSCRIPTION c2.REACTOME FOXO MEDIATED TRANSCRIPTION c2.REACTOME SIGNALING BY ERYTHROPOIETIN c2.REACTOME SIGNALING BY ERYTHROPOIETIN c2.CAMIT TESPONSE 60 HELA					
C2.REACTOME SIGNALING BY ERYTHROPOIETIN C2.AMIT EGF RESPONSE 60 HELA C2.REACTOME RUNX3 REGULATES NOTCH SIGNALING C2.KEGG MEDICUS REFERENCE BRANCHING MICROTUBULE NUCLEATION C2.JECHLINGER EPITHELIAL TO MESENCHYMAL TRANSITION DN C2.DACOSTA UV RESPONSE VIA ERCC3 TTD UP C2.GRADE COLON AND RECTAL CANCER UP C2.REACTOME ROTOM SURVIVAL OVERALL DN C2.REACTOME NOTCH3 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS C2.REACTOME DEADENYLATION DEPENDENT MRNA DECAY C2.REACTOME DEADENYLATION DEPENDENT MRNA DECAY C2.REACTOME ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION C2.SESTO RESPONSE TO UV C6 C2.MAYBURD RESPONSE TO L663536 UP C2.REACTOME RESPONSE TO METAL IONS C2.WP HOSTPATHOGEN INTERACTION OF HUMAN CORONAVIRUSES MAPK SIGNALING C2.BIOCARTA PARKIN PATHWAY C2.DACOSTA UV RESPONSE VIA ERCC3 TTD DN C2.REACTOME KILLING MECHANISMS					
c2.DACOSTA UV RESPONSE VIA ERCC3 TTD DN c2.REACTOME KILLING MECHANISMS c2.REACTOME INHIBITION OF DNA RECOMBINATION AT TELOMERE c2.NAKAYAMA FRAZ TARGETS c2.BIOCARTA CHREBP PATHWAY c2.REACTOME CH.I INTERACTIONS c2.BIOCARTA GATAS PATHWAY c2.CAIRO PML TARGETS BOUND BY MYC UP c2.REACTOME FACTORS INVOLVED IN MEGAKARYOCYTE DEVELOPMENT AND PLATELET PRODUCTION c2.REACTOME WNT MEDIATED ACTIVATION OF DVL c2.PLD ENDOTHELIN PATHWAY c2.REACTOME MAPK FAMILY SIGNALING CASCADES c2.FRIDMAN SENESCENCE DN c2.REACTOME NPAS4 REGULATES EXPRESSION OF TARGET GENES c2.REACTOME NPAS4 REGULATES EXPRESSION OF TARGET GENES c2.REACTOME DEVELOPMENTAL BIOLOGY c2.HAHTOLA MYCOSIS FUNGOIDES DN c2.PHONG TNF RESPONSE VIA P38 COMPLETE c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT PSEN TO MGLUR5 CA2 APOPTOTIC PATHWAY c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT PSEN TO MGLUR5 CA2 APOPTOTIC PATHWAY c2.KEGG MEDICUS REFERENCE P4 PR PISK SIGNALING PATHWAY					
C2.KEGG MEDICUS REFERENCE P4 PR PI3K SIGNALING PATHWAY C2.REACTOME RHO GTPASES ACTIVATE FORMINS C2.DEBIASI APOPTOSIS BY REOVIRUS INFECTION DN C2.MONNIER POSTRADIATION TUMOR ESCAPE UP C2.REACTOME PROSTACYCLIN SIGNALLING THROUGH PROSTACYCLIN RECEPTOR C2.ZHANG BREAST CANCER PROGENITORS DN C2.KEGG MEDICUS REFERENCE IGF2 IGF1 R PI3K SIGNALING PATHWAY C2.KEGG MEDICUS PATHOGEN SALMONELLA SOPB TO RHOG SIGNALING PATHWAY C2.KEGG MEDICUS PATHOGEN SALMONELLA SOPB TO RHOG SIGNALING PATHWAY C2.CNOGUSAHA TP53 TARGETS C2.REACTOME GLUCAGON SIGNALING IN METABOLIC REGULATION C2.MEINHOLD OVARIAN CANCER LOW GRADE UP C2.MATTHEWS AP1 TARGETS C2.VALK AML CLUSTER 11 C2.LIU SOX4 TARGETS UP C2.CROMER TUMORIGENESIS UP C2.KEGG MEDICUS REFERENCE CCR2 GNB G PI3K NFKB SIGNALING PATHWAY C2.GOLUB ALL VS AML DN C2.REACTOME TICAM1 DEPENDENT ACTIVATION OF IRF3 IRF7 C2.BIOCARTA EEA1 PATHWAY					
c2.KEGG MEDICUS REFERENCE TGFA EGFR PLCG PKC SIGNALING PATHWAY c2.REACTOME RAB REGULATION OF TRAFFICKING c2.WP OXIDATIVE STRESS RESPONSE c2.REACTOME SUMOYLATION OF TRANSCRIPTION FACTORS c2.KEGG MEDICUS REFERENCE KITLG KIT PI3K SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE KITLG KIT PI3K SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE KITLG KIT PI3K SIGNALING PATHWAY c2.RASHI RESPONSE TO IONIZING RADIATION 3 c2.WP TARGET OF RAPAMYCIN SIGNALING c2.LEIN LOCALIZED TO DISTAL AND PROXIMAL DENDRITES c2.WANG RECURRENT LIVER CANCER DN c2.DARWICHE SQUAMOUS CELL CARCINOMA UP c2.THAN ZNF143 PARTNERS c2.ZHU CMV ALL UP c2.MAGRANGEAS MULTIPLE MYELOMA IGG VS IGA UP c2.REACTOME NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION c2.WP NODLIKE RECEPTOR NLR SIGNALING c2.SENESE HDAC2 TARGETS UP c2.REACTOME CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION c2.GUTIERREZ WALDENSTROEMS MACROGLOBULINEMIA 1 UP					
C2.ZAMORA NOS2 TARGETS UP C2.REACTOME PLATELET ADHESION TO EXPOSED COLLAGEN C2.REACTOME ASSEMBLY AND CELL SURFACE PRESENTATION OF NMDA RECEPTORS C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO TRANSPORT OF CALCIUM C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO MACHR CA2 APOPTOTIC PATHWAY C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO MACHR CA2 APOPTOTIC PATHWAY C2.REACTOME ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION C2.WP LIPID METABOLISM PATHWAY C2.KEGG REGULATION OF ACTION CYTOSKELETON C2.REACTOME NOSTRIN MEDIATED ENOS TRAFFICKING C2.WP LACTATE SHUTTLE IN GLIAL CELLS C2.GRUETZMANN PANCREATIC CANCER DN C2.AMIT DELAYED EARLY GENES C2.BIOCARTA IL3 PATHWAY C2.WP CANNABINOID RECEPTOR SIGNALING C2.WP S1P RECEPTOR SIGNALING C2.GREENBAUM E2A TARGETS DN					
c2.BENPORATH SOX2 TARGETS c2.WENG POR DOSAGE c2.VANDESLUIS NORMAL EMBRYOS DN c2.HAMAI APOPTOSIS VIA TRAIL UP c2.MARIADASON RESPONSE TO CURCUMIN SULINDAC 5 c2.KEGG MEDICUS REFERENCE PRNP PI3K NOX2 SIGNALING PATHWAY c2.CARD MIR302A TARGETS c2.GENTILE UV HIGH DOSE DN c2.KEGG MEDICUS REFERENCE AVP V2R PKA SIGNALING PATHWAY c2.GRAESSMANN APOPTOSIS BY DOXORUBICIN DN c2.KEGG MEDICUS REFERENCE REGULATION OF FIBRINOLYTIC SYSTEM PAI c2.BIOCARTA CERAMIDE PATHWAY c2.TURASHVILI BREAST DUCTAL CARCINOMA VS DUCTAL NORMAL UP c2.REACTOME MITF M DEPENDENT GENE EXPRESSION c2.REACTOME TRANSCRIPTIONAL REGULATION OF BROWN AND BEIGE ADIPOCYTE DIFFERENTIATION c2.WP MAPK AND NFKB SIGNALING INHIBITED BY YERSINIA YOPJ c2.REACTOME SIRT1 NEGATIVELY REGULATES RRNA EXPRESSION					
c2.ZHANG TARGETS OF EWSR1 FLI1 FUSION c2.WILCOX RESPONSE TO PROGESTERONE DN c2.GHO ATF5 TARGETS UP c2.BIOCARTA GH PATHWAY c2.KEGG MEDICUS VARIANT AMPLIFIED CDK4 TO CELL CYCLE G1 S c2.DARWICHE SKIN TUMOR PROMOTER UP c2.REACTOME RAC3 GTPASE CYCLE c2.WANG LMO4 TARGETS DN c2.BIOCARTA EGFR SMRTE PATHWAY c2.WP GROWTH FACTORS AND HORMONES IN BETA CELL PROLIFERATION c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED AXIN TO WNT SIGNALING PATHWAY c2.AMIT SERUM RESPONSE 40 MCF10A c2.PROVENZANI METASTASIS UP c2.BILD SRC ONCOGENIC SIGNATURE c2.KEGG MEDICUS PATHOGEN SALMONELLA SOPE E2 TO NOD NFKB SIGNATURE c2.KEGG MEDICUS PATHOGEN SALMONELLA SOPE E2 TO NOD NFKB SIGNATURE c2.KEGG MEDICUS PATHOGEN SALMONELLA SOPE C2.DACAERI BREAST CANCER BRCA1 VS BRCA2 UP c2.MCCLUNG CREB1 TARGETS UP c2.KEGG SNARE INTERACTIONS IN VESICULAR TRANSPORT c2.JIANG TIP30 TARGETS UP					
c2.WP MAP3K1 ROLE IN PROMOTING AND BLOCKING GONADAL DETERMINATION c2.WP CALORIC RESTRICTION AND AGING c2.RODWELL AGING KIDNEY NO BLOOD UP c2.AMIT EGF RESPONSE 40 MCF10A c2.CAVARD LIVER CANCER MALIGNANT VS BENIGN c2.STEGER ADIPOGENESIS DN c2.REACTOME RNA POLYMERASE I TRANSCRIPTION INITIATION c2.REACTOME MET ACTIVATES PTPN11 c2.KEGG MEDICUS REFERENCE ERK RSK SIGNALING c2.GERHOLD ADIPOGENESIS UP c2.BURTON ADIPOGENESIS UP c2.BURTON ADIPOGENESIS 5 c2.BUYTAERT PHOTODYNAMIC THERAPY STRESS UP c2.TERAMOTO OPN TARGETS CLUSTER 6 c2.CHEOK RESPONSE TO MERCAPTOPURINE AND HD MTX DN c2.KIM GERMINAL CENTER T HELPER DN c2.RADMACHER AML PROGNOSIS c2.RADMACHER AML PROGNOSIS c2.RADMACHER AML PROGNOSIS					
c2.PEART HDAC PROLIFERATION CLUSTER UP c2.REACTOME RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN INTERLEUKIN SIGNALING c2.TURASHVILI BREAST LOBULAR CARCINOMA VS LOBULAR NORMAL DN c2.REACTOME SIGNALING BY ERBB2 IN CANCER c2.REACTOME SIGNALING BY ERBB2 IN CANCER c2.REACTOME PLASMA LIPOPROTEIN CLEARANCE c2.REACTOME SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE c2.WP RANKLRANK SIGNALING c2.NEBEN AML WITH FLT3 OR NARS DN c2.MARTINEZ RB1 TARGETS UP c2.WP SYNAPTIC SIGNALING ASSOCIATED WITH AUTISM SPECTRUM DISORDER c2.DIRMEIER LMP1 RESPONSE LATE UP c2.WP AMYOTROPHIC LATERAL SCLEROSIS ALS c2.JINESH BLEBBISHIELD TO IMMUNE CELL FUSION PBSHMS UP c2.DORN ADENOVIRUS INFECTION 12HR UP c2.ELVIDGE HYPOXIA DN c2.REACTOME SIGNAL AMPLIFICATION c2.BURTON ADIPOGENESIS 2 c2.AMIT EGF RESPONSE 240 HELA c2.LANDIS ERBB2 BREAST TUMORS 324 DN					
C2.STEARMAN LUNG CANCER EARLY VS LATE DN C2.REACTOME ECM PROTEOGLYCANS C2.CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS UP C2.REACTOME GLUCAGON LIKE PEPTIDE 1 GLP1 REGULATES INSULIN SECRETION C2.LEE LIVER CANCER MYC UP C2.CAIRO HEPATOBLASTOMA CLASSES UP C2.REACTOME TRANSCRIPTIONAL REGULATION BY MECP2 C2.PID ECADHERIN STABILIZATION PATHWAY C2.JISON SICKLE CELL DISEASE UP C2.GLASS IGF2BP1 CLIP TARGETS KNOCKDOWN DN C2.KEGG MEDICUS REFERENCE PLASMIN MEDIATED ACTIVATION OF LATENT TGF BETA C2.BARRIER CANCER RELAPSE TUMOR SAMPLE UP C2.UEDA CENTRAL CLOCK C2.PID S1P META PATHWAY C2.CROONQUIST STROMAL STIMULATION DN C2.REACTOME COMPLEX IV ASSEMBLY C2.PODAR RESPONSE TO ADAPHOSTIN UP C2.CAIRO LIVER DEVELOPMENT UP					
C2.VETTER TARGETS OF PRKCA AND ETS1 UP C2.WP DDX1 AS A REGULATORY COMPONENT OF THE DROSHA MICROPROCESSOR C2.KYNG ENVIRONMENTAL STRESS RESPONSE NOT BY UV IN WS C2.KAPOSI LIVER CANCER MET DN C2.PID TELOMERASE PATHWAY C2.MATTIOLI MULTIPLE MYELOMA WITH 14Q32 TRANSLOCATIONS C2.GAVIN FOXP3 TARGETS CLUSTER T4 C2.MCBRYAN PUBERTAL BREAST 4 5WK DN C2.CHEN HOXAS TARGETS 6HR UP C2.HUMMERICH SKIN CANCER PROGRESSION DN C2.CHEN HOXAS TARGETS OF MULTIPLE OF NUCLEOSIDES AND FREE PURINE AND PYRIMIDINE BASES ACROSS THE PLASMA MEMBRANE C2.TURJANSKI MAPK7 TARGETS C2.REACTOME TRANSPORT OF NUCLEOSIDES AND FREE PURINE AND PYRIMIDINE BASES ACROSS THE PLASMA MEMBRANE C2.VARELA ZMPSTE24 TARGETS UP C2.KEGG LEUKOCYTE TRANSLESION SYNTHESIS BY POLK C2.VARELA ZMPSTE24 TARGETS UP C2.KEGG LEUKOCYTE TRANSENDOTHELIAL MIGRATION C2.KEGG MEDICUS VARIANT LOSS OF NKX3 1 TO PI3K SIGNALING PATHWAY C2.STAMBOLSKY TARGETS OF MUTATED TP53 UP C2.KEGG MEDICUS REFERENCE BMP15 SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE BMP15 SIGNALING PATHWAY					patho_cat_name Nerve sheath tumors Spindle and epithelioid tumors Gliomas Glioneuronal tumors
c2.ZHENG GLIOBLASTOMA PLASTICITY DN c2.MOOTHA PYR c2.REACTOME OPIOID SIGNALLING c2.WP INCLUSION BODY MYOSITIS c2.KEGG NON SMALL CELL LUNG CANCER c2.WP NEUROINFLAMMATION c2.REACTOME REGULATION OF INSULIN LIKE GROWTH FACTOR IGF TRANSPORT AND UPTAKE BY INSULIN LIKE GROWTH FACTOR BINDING PROTEINS IGFBPS c2.PUJANA CHEK2 PCC NETWORK c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED PINK1 TO INTRINSIC APOPTOTIC PATHWAY NO1050 c2.REACTOME RND1 GTPASE CYCLE c2.WEST ADRENOCORTICAL TUMOR UP c2.CHESLER BRAIN QTL CIS c2.REACTOME PKA ACTIVATION IN GLUCAGON SIGNALLING c2.VANHARANTA UTERINE FIBROID UP c2.REACTOME MET ACTIVATES PTK2 SIGNALING c2.KEGG MEDICUS REFERENCE C9ORF72 MEDIATED AUTOPHAGY INITIATION c2.BOYAULT LIVER CANCER SUBCLASS G12 UP c2.REACTOME TRANSCRIPTIONAL REGULATION BY SMALL RNAS					
c2.WP SPLICING FACTOR NOVA REGULATED SYNAPTIC PROTEINS c2.CHESLER BRAIN HIGHEST GENETIC VARIANCE c2.PURWIN MEWO SOX10 TARGETS c2.AMUNDSON RESPONSE TO ARSENITE c2.CAMUNDSON RESPONSE TO ARSENITE c2.CAMUNDS BREAST CANCER PROGRESSION DN c2.KEGG MEDICUS REFERENCE CXCR4 GNB GP LICE BY KE SIGNALING PATHWAY c2.PUIFFE INVASION INHIBITED BY ASCITES DN c2.WP RETT SYNDROME c2.LOCKWOOD AMPLIFIED IN LUNG CANCER c2.KEGG MEDICUS REFERENCE MGLUR5 CA2 APOPTOTIC PATHWAY c2.YORDY RECIPROCAL REGULATION BY ETS1 AND SP100 UP c2.CHIN BREAST CANCER COPY NUMBER DN c2.REACTOME NEUROFASCIN INTERACTIONS c2.WONG EMBRYONIC STEM CELL CORE c2.ZEILSTRA CD44 TARGETS UP c2.REACTOME PISP REGULATES TP53 ACETYLATION					
c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED PRKACA TO ACTH CORTISOL SIGNALING PATHWAY c2.WP ARYL HYDROCARBON RECEPTOR PATHWAY WP2586 c2.REACTOME SIGNALING BY FGFR IN DISEASE c2.PID SHP2 PATHWAY c2.PID INTEGRIN3 PATHWAY c2.PID INTEGRIN3 PATHWAY c2.MARTINEZ RB1 AND TP53 TARGETS DN c2.BOYAULT LIVER CANCER SUBCLASS G5 DN c2.WP SREBF AND MIR33 IN CHOLESTEROL AND LIPID HOMEOSTASIS c2.REACTOME MYOGENESIS c2.REACTOME MYOGENESIS c2.REACTOME MYOGENESIS c2.KEGG MEDICUS PATHOGEN KSHV VGPCR TO GNB G PI3K JNK SIGNALING PATHWAY c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED RET TO PI3K SIGNALING PATHWAY c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED RET TO PI3K SIGNALING PATHWAY c2.WP ERK PATHWAY IN HUNTINGTONS DISEASE c2.WP G PROTEIN SIGNALING C2.MARTINEZ TP53 TARGETS DN c2.PARK APL PATHOGENESIS DN c2.HUMMERICH MALIGNANT SKIN TUMOR UP					
C2.REACTOME INTRAFLAGELLAR TRANSPORT C2.REACTOME BINDING AND UPTAKE OF LIGANDS BY SCAVENGER RECEPTORS C2.WALLACE JAK2 TARGETS UP C2.KEGG MEDICUS REFERENCE BMP HAMP SIGNALING PATHWAY C2.WP CONSTITUTIVE ANDROSTANE RECEPTOR PATHWAY C2.WP CONSTITUTIVE ANDROSTANE RECEPTOR PATHWAY C2.REACTOME SIGNALING BY NOTCH3 C2.MYLLYKANGAS AMPLIFICATION HOT SPOT 7 C2.KEGG MEDICUS REFERENCE EGF EGF P13K NFKB SIGNALING PATHWAY C2.HOEBEKE LYMPHOID STEM CELL DN C2.REACTOME SUMOYLATION OF CHROMATIN ORGANIZATION PROTEINS C2.REACTOME SUMOYLATION OF CHROMATIN ORGANIZATION PROTEINS C2.GADBERT OLIGODENDROCYTE DIFFERENTIATION DN C2.VANHARANTA UTERINE FIBROID WITH 7Q DELETION UP C2.AMIT EGF RESPONSE 480 HELA C2.GARGALOVIC RESPONSE TO CXIDIZED PHOSPHOLIPIDS TAN DN C2.REACTOME FORMATION OF APOPTOSOME C2.PURWIN A375 MEWO COMMON SOX10 TARGETS C2.FURWIN A375 MEWO COMMON SOX10 TARGETS C2.REACTOME HIV ELONGATION ARREST AND RECOVERY					
C2.BIOCARTA CIRCADIAN PATHWAY C2.CASTELLANO HRAS AND NRAS TARGETS UP C2.KEGG MEDICUS PATHOGEN HCMV US28 TO GNAQ PLCB G CALCINEURIN SIGNALING PATHWAY C2.REACTOME G BETA GAMMA SIGNALLING THROUGH PI3KGAMMA C2.PID INTEGRIN A981 PATHWAY C2.REACTOME FORMATION OF THE BETA CATENIN TCF TRANSACTIVATING COMPLEX C2.MCCABE HOXC6 TARGETS DN C2.LEE LIVER CANCER E2F1 UP C2.PID INTEGRIN 1PATHWAY C2.MORI SMALL PRE BII LYMPHOCYTE UP C2.REACTOME RAB GERANYLGERANYLATION C2.REACTOME DISEASES OF PROGRAMMED CELL DEATH C2.NAKAMURA CANCER MICROENVIRONMENT UP C2.BURCHDEWALD SKIN CARCINOGENESIS DN C2.BENITEZ GBM PROTEASOME INHIBITION RESPONSE C2.WP NAD METABOLISM SIRTUINS AND AGING C2.REACTOME CILL DEATH C2.NAKAMURA CANCER MICROENVIRONMENT UP C2.BENITEZ GBM PROTEASOME INHIBITION RESPONSE C2.WP NAD METABOLISM SIRTUINS AND AGING C2.WANG LSD1 TARGETS UP C2.INGA TP53 TARGETS C2.MA RAT AGING UP					
C2.WP JAKSTAT SIGNALING IN THE REGULATION OF BETA CELLS C2.LANDIS ERBB2 BREAST PRENEOPLASTIC DN C2.HU GENOTOXIN ACTION DIRECT VS INDIRECT 4HR C2.TCGA GLIOBLASTOMA COPY NUMBER UP C2.HOLLEMAN DAUNORUBICIN ALL DN C2.YANG BREAST CANCER ESR1 BULK UP C2.GRYDER PAX3FOXO1 TOP ENHANCERS C2.GRYDER PAX3FOXO1 TOP ENHANCERS C2.WP KREBS CYCLE DISORDERS C2.WP KREBS CYCLE DISORDERS C2.WP KREBS CYCLE DISORDERS C2.DASU IL6 SIGNALING SCAR UP C2.LIANG HEMATOPOIESIS STEM CELL NUMBER SMALL VS HUGE UP C2.HAHTOLA CTCL CUTANEOUS C2.REACTOME BASIGIN INTERACTIONS C2.REACTOME BASIGIN INTERACTIONS C2.REACTOME SIGNALING BY NOTCH2 C2.KYNG ENVIRONMENTAL STRESS RESPONSE NOT BY 4NQO IN WS C2.PUJANA BRCA1 PCC NETWORK C2.WAMUNYOKOLI OVARIAN CANCER GRADES 1 2 DN C2.GINESTIER BREAST CANCER ZIF217 AMPLIFIED UP					
C2.REACTOME ERYTHROPOIETIN ACTIVATES PHOSPHOLIPASE C GAMMA PLCG C2.KEGG MEDICUS REFERENCE AMH SIGNALING PATHWAY C2.SANA THS SIGNALING DN C2.WP EXTRACELLULAR VESICLES IN THE CROSSTALK OF CARDIAC CELLS C2.REACTOME SLBP DEPENDENT PROCESSING OF REPLICATION DEPENDENT HISTONE PRE MRNAS C2.BIOCARTA MAPK PATHWAY C2.KAAB HEART ATRIUM VS VENTRICLE UP C2.REACTOME CONDENSATION OF PROPHASE CHROMOSOMES C2.REACTOME ACTIVATION OF ANTERIOR HOX GENES IN HINDBRAIN DEVELOPMENT DURING EARLY EMBRYOGENESIS C2.REACTOME ANTI INFLAMMATORY RESPONSE FAVOURING LEISHMANIA PARASITE INFECTION C2.REACTOME ARACHIDONATE PRODUCTION FROM DAG C2.REACTOME ARACHIDONATE PRODUCTION FROM DAG C2.REACTOME SARS COV 1 ACTIVATES MODULATES INNATE IMMUNE RESPONSES C2.REACTOME NEF AND SIGNAL TRANSDUCTION C2.GENTILE UV LOW DOSE DN C2.KEGG MEDICUS REFERENCE TNF JNK SIGNALING PATHWAY C2.KAYO CALORIE RESTRICTION MUSCLE DN C2.WP AP163 COPY NUMBER VARIATION C2.WP REGUCALCIN IN PROXIMAL TUBULE EPITHELIAL KIDNEY CELLS					
c2. SENESE HDAC1 TARGETS UP c2. MAINA HYPOXIA VHL TARGETS UP c2. MAINA HYPOXIA VHL TARGETS UP c2. MAINA HYPOXIA VHL TARGETS UP c2. HOLLERN EMT BREAST TUMOR UP c2. SIG BCR SIGNALING PATHWAY c2. MORI SMALL PRE BIL LYMPHOCYTE DN c2. REACTOME RIPK1 MEDIATED REGULATED NECROSIS c2. REACTOME MET INTERACTS WITH TNS PROTEINS c2. C. CHANGOLKAR H2AFY TARGETS UP c2. WANG RESPONSE TO ANDROGEN UP c2. WOOD EBV EBNA1 TARGETS UP c2. WOOD EBV EBNA1 TARGETS UP c2. BIOCARTA SPPA PATHWAY c2. KEGG MEDICUS REFERENCE IL1 IL7 JNK SIGNALING PATHWAY c2. REACTOME REGULATION OF HSF1 MEDIATED HEAT SHOCK RESPONSE c2. KEGG MEDICUS REFERENCE CXCR4 GNAQ PLCB G CALCINEURIN SIGNALING PATHWAY c2. REACTOME REGULATION OF HSF1 MEDIATED HEAT SHOCK RESPONSE c2. KEGG MEDICUS REFERENCE CXCR4 GNAQ PLCB G CALCINEURIN SIGNALING PATHWAY c2. REACTOME REGULATION UP c2. BOYAULT LIVER CANCER SUBCLASS G1 UP c2. CALINSKY CANCER DEATH UP					
c2.KEGG MEDICUS VARIANT AMPLIFIED MYC TO CELL CYCLE G1 S c2.CHESLER BRAIN D6MIT150 QTL TRAMS c2.BIOCARTA SARS PATHWAY c2.WU ALZHEIMER DISEASE DN c2.PURWIN A375 SOX10 TARGETS c2.KOBAYASHI EGFR SIGNALING 24HR UP c2.REACTOME IKK COMPLEX RECRUITMENT MEDIATED BY RIP1 c2.REACTOME NCAM SIGNALING FOR NEURITE OUT GROWTH c2.LANDIS ERBB2 BREAST TUMORS 324 UP c2.MARIADASON REGULATED BY HISTONE ACETYLATION UP c2.MISSIAGLIA REGULATED BY METHYLATION UP c2.MISSIAGLIA REGULATED BY METHYLATION UP c2.BIOCARTA NO1 PATHWAY c2.REACTOME RUNX1 REGULATES EXPRESSION OF COMPONENTS OF TIGHT JUNCTIONS c2.KEGG MEDICUS REFERENCE CX3CR1 GNAI AC PKA SIGNALING PATHWAY c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED EGFR TO PI3K SIGNALING PATHWAY c2.WANG ESOPHAGUS CANCER VS NORMAL UP c2.YAO HOXA10 TARGETS VIA PROGESTERONE DN c2.SHIN B CELL LYMPHOMA CLUSTER 7					
c2.UEDA PERIFERAL CLOCK c2.HELLER HDAC TARGETS UP c2.MCDOWELL ACUTE LUNG INJURY UP c2.MCDOWELL ACUTE LUNG INJURY UP c2.WP SELENIUM METABOLISM AND SELENOPROTEINS c2.REACTOME MITOCHONDRIAL FATTY ACID BETA OXIDATION OF SATURATED FATTY ACIDS c2.GOTTWEIN TARGETS OF KSHV MIR K12 11 c2.PID ANTHRAX PATHWAY c2.KEGG MEDICUS VARIANT ESR1 POSITIVE TO NUCLEAR INITIATED ESTROGEN SIGNALING PATHWAY c2.KEGG MEDICUS PATHOGEN HCMV UL33 TO GNAI AC PKA SIGNALING PATHWAY c2.KEGG MEDICUS PATHOGEN HCMV UL33 TO GNAI AC PKA SIGNALING PATHWAY c2.REACTOME BUTYRATE RESPONSE FACTOR 1 BRF1 BINDS AND DESTABILIZES MRNA c2.REACTOME BUTYRATE RESPONSE FACTOME GLYCOGEN STORAGE DISEASES c2.KEGG MEDICUS REFERENCE P300 P21 CELL CYCLE G1 S c2.CHOW RASSF1 TARGETS DN c2.HUMMERICH SKIN CANCER PROGRESSION UP c2.GRYDER PAX3FOXO1 ENHANCERS IN TADS c2.LEE LIVER CANCER HEPATOBLAST c2.ACEVEDO LIVER TUMOR VS NORMAL ADJACENT TISSUE UP c2.WP CCL18 SIGNALING					
C2.BAKKER FOXO3 TARGETS UP C2.CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS DN C2.HOLLMANN APOPTOSIS VIA CD40 UP C2.SA FAS SIGNALING C2.WP DISORDERS IN KETONE BODY SYNTHESIS C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED PINK1 TO INTRINSIC APOPTOTIC PATHWAY N01048 C2.REACTOME SYNTHESIS OF PIPS AT THE GOLGI MEMBRANE C2.HOFFMANN SMALL PRE BII TO IMMATURE B LYMPHOCYTE DN C2.SCHLOSSER SERUM RESPONSE UP C2.WP TGFBETA RECEPTOR SIGNALING IN SKELETAL DYSPLASIAS C2.DELASERNA MYOD TARGETS DN C2.OSWALD HEMATOPOIETIC STEM CELL IN COLLAGEN GEL DN C2.BROWNE HCMV INFECTION 20HR DN C2.KEGG MEDICUS REFERENCE TRANSCRIPTION COUPLED NER C2.LI WILMS TUMOR VS FETAL KIDNEY 1 UP C2.REACTOME TNF SIGNALING C2.WP UROTENSINIIMEDIATED SIGNALING C2.LY AGING OLD DN					
c2.WINTER HYPOXIA METAGENE c2.DAZARD UV RESPONSE CLUSTER G24 c2.REACTOME CREB1 PHOSPHORYLATION THROUGH NMDA RECEPTOR MEDIATED ACTIVATION OF RAS SIGNALING c2.JEPSEN SMRT TARGETS c2.HOFFMANN PRE BI TO LARGE PRE BII LYMPHOCYTE DN c2.HAN JNK SINGALING UP c2.WP NRP1TRIGGERED SIGNALING IN PANCREATIC CANCER c2.XU GH1 AUTOCRINE TARGETS DN c2.REACTOME ROLE OF PHOSPHOLIPIDS IN PHAGOCYTOSIS c2.ZHANG BREAST CANCER PROGENITORS UP c2.GUO TARGETS OF IRS1 AND IRS2 c2.WP ID SIGNALING c2.REACTOME AKT PHOSPHORYLATES TARGETS IN THE NUCLEUS c2.REACTOME SYNTHESIS OF 5 EICOSATETRAENOIC ACIDS c2.KEGG MEDICUS PATHOGEN KSHV VFLIP TO TNF NFKB SIGNALING PATHWAY c2.KORKOLA YOLK SAC TUMOR UP c2.DANG REGULATED BY MYC UP c2.TONKS TARGETS OF RUNX1 RUNX1T1 FUSION MONOCYTE UP c2.KYNG NORMAL AGING DN					
C2.ZERBINI ŘEŠPONSÉ TO SULINDÁC UP C2.YAGUE PRETUMOR DRUG RESISTANCE DN C2.KEGG LYSINE DEGRADATION C2.BURTON ADIPOGENESIS 10 C2.REACTOME APOPTOTIC CLEAVAGE OF CELL ADHESION PROTEINS C2.REACTOME ADAPTIVE IMMUNE SYSTEM C2.KEGG MEDICUS REFERENCE TLR3 NFKB SIGNALING PATHWAY C2.REACTOME YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION C2.HOWLIN CITED1 TARGETS 1 DN C2.WP INITIATION OF TRANSCRIPTION AND TRANSLATION ELONGATION AT THE HIV1 LTR C2.KIM WT1 TARGETS 12HR DN C2.EACTOME P75 NTR RECEPTOR MEDIATED SIGNALLING C2.WP NIPBL ROLE IN DNA DAMAGE CORNELIA DE LANGE SYNDROME C2.KEGG MEDICUS REFERENCE METHIONINE DEGRADATION C2.KEGG MEDICUS REFERENCE METHIONINE DEGRADATION C2.WP ANGIOPOIETINLIKE PROTEIN 8 REGULATORY PATHWAY C2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 9					
c2. TAOUTEMPORAL RESPONSE TO PROGESTER/OP CLUSTER 9 c2. BROWNE HCMV INFECTION 24HR DN c2. GARY CD5 TARGETS UP c2. KEGG MEDICUS VARIANT MUTATION INACTIVATED PDE11A PDE8B TO ACTH CORTISOL SIGNALING PATHWAY c2. DATA OR THE POND STANDAY OR C2. DER IFN GAMMA RESPONSE UP c2. RAO BOUND BY SALL4 c2. ZIRN TRETINOIN RESPONSE WIT UP c2. RAO BOUND BY SALL4 c2. ZIRN TRETINOIN RESPONSE WIT UP c2. UDAYAKUMAR MED1 TARGETS UP c2. PID TCR CALCIUM PATHWAY c2. PID TCR CALCIUM PATHWAY c2. REJONARESPONSE TO TNF UP c2. HEIDENBLAD AMPLIFIED IN PANCREATIC CANCER c2. PID RESPONSE TO THE UP c2. KEGG MEDICUS REFERENCE BCR BCAP CD19 PI3K SIGNALING PATHWAY c2. BYSTRYKH HEMATOPOIESIS STEM CELL AND BRAIN QTL TRANS c2. XU CREBBP TARGETS DN c2. WEREBP TARGETS SIGNALING					
C2.PATIL LIVER CANCER C2.REACTOME PRE NOTCH PROCESSING IN GOLGP C2.SCHAEFFER PROSTATE DEVELOPMENT AND CANCER BOX6 UP C2.KIM ALL DISORDERS DURATION CORR UP C2.KIM ALL DISORDERS DURATION CORR UP C2.KIM SEY TARGETS OF EWSR1 FLII FUSION DN C2.WP HOSTPATHOGEN INTERACTION OF HUMAN CORONAVIRUSES AUTOPHAGY C2.WP HOSTPATHOGEN INTERACTION OF HUMAN CORONAVIRUSES AUTOPHAGY C2.REACTOME NR1H2 NR1H3 REGULATE GENE EXPRESSION TO CONTROL BILE ACID HOMEOSTASIS C2.REACTOME GLUTAMATE NEUROTRANSMITTER RELEASE CYCLE C2.WP CILIARY LANDSCAPE C2.KEGG MEDICUS PATHOGEN HCMV UL33 TO GNB G RHO SIGNALING PATHWAY C2.WP RAS SIGNALING C2.KOMMAGANI TP63 GAMMA TARGETS C2.BRACHAT RESPONSE TO CAMPTOTHECIN UP C2.NAKAMURA ADIPOGENESIS LATE UP C2.REACTOME MICRORNA MIRNA BIOGENESIS C2.WP INTERFERONMEDIATED SIGNALING C2.KEGG MEDICUS VARIANT LOSS OF RASSF1 TO RAS RASSF1 SIGNALING PATHWAY C2.MARTINEZ TP53 TARGETS UP					
C2. JI RESPONSE TO FSH UP C2.REACTOME PROCESSING OF SMDT1 C2.MARTINEZ RB1 AND TP53 TARGETS UP C2.ACEVEDO LIVER CANCER UP C2.AGUIRRE PANCREATIC CANCER COPY NUMBER DN C2.PID FRA PATHWAY C2.KEGG MEDICUS REFERENCE ITGA B FAK RAC SIGNALING PATHWAY C2.SNIJDERS AMPLIFIED IN HEAD AND NECK TUMORS C2.SNIJDERS AMPLIFIED IN HEAD AND NECK TUMORS C2.SUBURTON ADIPOGENESIS 6 C2.KEGG MEDICUS PATHOGEN HCV CORE TO RXRA PPARA MEDIATED TRANSCRIPTION C2.REACTOME CROSSLINKING OF COLLAGEN FIBRILS C2.WP MIR5093P ALTERATION OF YAP1ECM AXIS C2.RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED DN C2.CHEOK RESPONSE TO HD MTX DN C2.CHEOK RESPONSE TO HD MTX DN C2.WANG CLIM2 TARGETS DN C2.REACTOME FORMATION OF RNA POL II ELONGATION COMPLEX C2.CAIRO PML TARGETS BOUND BY MYC DN C2.WP ESTROGEN RECEPTOR PATHWAY					
c2.KIM GERMINAL CENTER T HELPER UP c2.SESTO RESPONSE TO UV C7 c2.BIOCARTA FREE PATHWAY c2.KEGG RNA DEGRADATION c2.REACTOME REGULATION OF PLK1 ACTIVITY AT G2 M TRANSITION c2.PID RAC1 REG PATHWAY c2.REACTOME RUNX3 REGULATES CDKN1A TRANSCRIPTION c2.WP ACUTE MYELOID LEUKEMIA c2.KEGG MEDICUS REFERENCE AREG EGFR PI3K SIGNALING PATHWAY c2.WP THYMIC STROMAL LYMPHOPOIETIN TSLP SIGNALING c2.WP CARDIAC HYPERTROPHIC RESPONSE c2.REACTOME TP53 REGULATES TRANSCRIPTION OF ADDITIONAL CELL CYCLE GENES WHOSE EXACT ROLE IN THE P53 PATHWAY REMAIN UNCERTAIN c2.ADDYA ERYTHROID DIFFERENTIATION BY HEMIN c2.MORI MATURE B LYMPHOCYTE UP c2.REACTOME CELL SURFACE INTERACTIONS AT THE VASCULAR WALL c2.KEGG MEDICUS REFERENCE P15 CELL CYCLE G1 S c2.KEGG CARDIAC MUSCLE CONTRACTION c2.DARWICHE PAPILLOMA RISK HIGH UP c2.REACTOME ACTIVATION OF GENE EXPRESSION BY SREBF SREBP					
C2.REACTOME ACTIVATION OF GENE EXPRESSION BY SREBF SREBP C2.BENPORATH NANOG TARGETS C2.REACTOME DISORDERS OF TRANSMEMBRANE TRANSPORTERS C2.LEE CALORIE RESTRICTION MUSCLE DN C2.KEGG MEDICUS VARIANT SCRAPIE CONFORMATION PRPSC TO TRANSPORT OF CALCIUM C2.WP PREGNANE X RECEPTOR PATHWAY C2.REACTOME DEX H BOX HELICASES ACTIVATE TYPE I IFN AND INFLAMMATORY CYTOKINES PRODUCTION C2.MARTINEZ RBI TARGETS DN C2.WP QUERCETIN AND NFKB API INDUCED APOPTOSIS C2.FOURNIER ACINAR DEVELOPMENT LATE 2 C2.KOKKINAKIS METHIONINE DEPRIVATION 96HR UP C2.CHUNG BLISTER CYTOTOXICITY UP C2.VICENT METASTASIS UP C2.NUTTTEN NIPP1 TARGETS DN C2.REACTOME INNATE IMMUNE SYSTEM C2.SARRIO EPITHELIAL MESENCHYMAL TRANSITION DN C2.CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA DN C3.CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA DN C4.CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA DN C4.CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA DN C4.CASORELLI ACUTE PROMYELOCYTIC PROMYELOCYTIC P					
c2.CHIARADONNA NEOPLASTIC TRANSFORMATION CDC25 DN c2.REACTOME FCGR3A MEDIATED IL10 SYNTHESIS c2.PALOMERO GSI SENSITIVITY DN c2.KEGG MEDICUS REFERENCE CHRNA7 E2F SIGNALING PATHWAY c2.YAGI AML WITH INV 16 TRANSLOCATION c2.REACTOME PROLACTIN RECEPTOR SIGNALING c2.REACTOME MITOCHONDRIAL CALCIUM ION TRANSPORT c2.REACTOME MITOCHONDRIAL CALCIUM ION TRANSPORT c2.REACTOME GPROTEIN BETA GAMMA SIGNALLING c2.REACTOME CHONDROITIN SULFATE METABOLISM c2.REACTOME KARP TARGETS OF P210 BCR ABL FUSION UP c2.ASTIER INTEGRIN SIGNALING c2.BERTUCCI MEDULLARY VS DUCTAL BREAST CANCER DN c2.KOINUMA TARGETS OF SMAD2 OR SMAD3 c2.REACTOME KSRP KHSRP BINDS AND DESTABILIZES MRNA c2.KEGG ACUTE MYELOID LEUKEMIA c2.GROSS HYPOXIA VIA LEKS AND HIF1A UP c2.CHANDRAN METASTASIS TOP50 DN c2.KYNG WERNER SYNDROM AND NORMAL AGING UP					
C2.TURJANSKI MAPK1 AND MAPK2 TARGETS C2.BIOCARTA MPR PATHWAY C2.REACTOME SEMA3A PLEXIN REPULSION SIGNALING BY INHIBITING INTEGRIN ADHESION C2.GOLUB ALL VS AML UP C2.WP PHASE I BIOTRANSFORMATIONS NONP450 C2.BOYAULT LIVER CANCER SUBCLASS G56 UP C2.TERAO AOX4 TARGETS SKIN UP C2.GAZDA DIAMOND BLACKFAN ANEMIA PROGENITOR DN C2.KEGG NOTCH SIGNALING PATHWAY C2.WP HIPPOYAP SIGNALING C2.REACTOME PERK REGULATES GENE EXPRESSION C2.NAKAMURA ADIPOGENESIS EARLY UP C2.KORKOLA EMBRYONIC CARCINOMA VS SEMINOMA UP C2.KEGG MEDICUS REFERENCE EREG EGFR PIЗK SIGNALING PATHWAY C2.RODRIGUES THYROID CARCINOMA ANAPLASTIC UP C2.REACTOME PKR MEDIATED SIGNALING C2.REACTOME PKR MEDIATED SIGNALING C2.KOROGENITAL GENERALIZED LIPODYSTROPHY C2.ROOTHA HUMAN MITODB 6 2002 C2.WP THIAMINE METABOLIC PATHWAYS C2.WANG BARRETTS ESOPHAGUS DN					
c2.WANG BARRETTS ESOPHAGUS DN c2.WANG RESPONSE TO FORSKOLIN DN c2.KYNG DNA DAMAGE BY 4NQO OR UV c2.KEGG MEDICUS REFERENCE TETHERING OF LATE ENDOSOMES AND LYSOSOMES c2.REACTOME SMALL INTERFERING RNA SIRNA BIOGENESIS c2.IBRAHIM NRF3 DOWN c2.KEGG MEDICUS REFERENCE MACHR CA2 APOPTOTIC PATHWAY c2.BIOCARTA DSP PATHWAY c2.BIOCARTA DSP PATHWAY c2.REACTOME ABORTIVE ELONGATION OF HIV 1 TRANSCRIPT IN THE ABSENCE OF TAT c2.REACTOME SYNTHESIS OF 15 EICOSATETRAENOIC ACID DERIVATIVES c2.RIZ ERYTHROID DIFFERENTIATION CONE1 c2.BIOCARTA FAS PATHWAY c2.NELSON RESPONSE TO ANDROGEN DN c2.HUANG DASATINIB SENSITIVITY UP c2.KYNG ENVIRONMENTAL STRESS RESPONSE NOT BY GAMMA IN OLD c2.SCHUETZ BREAST CANCER DUCTAL INVASIVE UP c2.NAGY PCAF COMPONENTS HUMAN c2.WP SPINAL CORD INJURY c2.REACTOME SYNTHESIS OF 15 EICOSATETRAENOIC C2.REACTOME SYNTHESIS OF 15 EICOSATETRAENOIC ACID DERIVATIVES					
C2.REACTOME SIGNALING BY NODAL C2.VANTVEER BREAST CANCER BRCA1 DN C2.SMITH TERT TARGETS UP C2.HUMMEL BURKITTS LYMPHOMA UP C2.WP T CELL RECEPTOR AND COSTIMULATORY SIGNALING C2.REACTOME CMPS IN SEMA3A SIGNALING C2.REACTOME CMPS IN SEMA3A SIGNALING C2.REACTOME OTHERS IN SEMA3A SIGNALING C2.WP MITOCHONDRIAL BETAOXIDATION C2.REACTOME OTHER SEMAPHORIN INTERACTIONS C2.REACTOME OTHER SEMAPHORIN INTERACTIONS C2.REACTOME CELL CYCLE MITOTIC C2.PID IL1 PATHWAY C2.KEGG MEDICUS ENV FACTOR NNK NNN TO PI3K SIGNALING PATHWAY N01339 C2.KEGG MEDICUS ENV FACTOR METALS TO KEAP1 NRF2 SIGNALIG PATHWAY C2.STEARMAN TUMOR FIELD EFFECT UP C2.KEGG MEDICUS REFERENCE BETA OXIDATION ACYL COA SYNTHESIS C2.DAZARD RESPONSE TO UV SCC DN C2.TSAI RESPONSE TO RADIATION THERAPY C2.XU HGF SIGNALING NOT VIA AKT1 48HR DN C2.WATZUK LUTEAL GENES					
C2.MATZUK LUTEAL GENES C2.REACTOME TRANSCRIPTIONAL REGULATION BY E2FE C2.BROCKE APOPTOSIS REVERSED BY IL6 C2.KEGG MEDICUS REFERENCE FGF FGFR RAS ERK SIGNALING PATHWAY C2.AGUIRRE PANCREATIC CANCER COPY NUMBER UP C2.REACTOME INTERLEUKIN 3 INTERLEUKIN 5 AND GM CSF SIGNALING C2.RIGGINS TAMOXIFEN RESISTANCE DN C2.REACTOME GLUTAMATE AND GLUTAMINE METABOLISM C2.REACTOME GLUTAMATE AND GLUTAMINE METABOLISM C2.REACTOME GAB1 SIGNALOSOME C2.DACOSTA UV RESPONSE VIA ERCC3 COMMON UP C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED MET TO PI3K SIGNALING PATHWAY C2.JECHLINGER EPITHELIAL TO MESENCHYMAL TRANSITION UP C2.REACTOME RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2 C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO TRANSPORT OF CALCIUM C2.SUH COEXPRESSED WITH ID1 AND ID2 UP C2.WP P38 MAPK SIGNALING C2.BECKER TAMOXIFEN RESISTANCE DN C2.REACTOME DAPIZ SIGNALING C2.KEGG MEDICUS REFERENCE TELOMERASE RNA MATURATION C2.KEGG MEDICUS REFERENCE TELOMERASE RNA MATURATION					
c2.BOYLAN MULTIPLE MYELOMA PCA1 DN c2.MCCLUNG COCAIN REWARD 4WK c2.BIOGARTA CELLCYCLE PATHWAY c2.POS RESPONSE TO HISTAMINE UP c2.WP DNA DAMAGE RESPONSE TO HISTAMINE UP c2.NIKOLSKY BREAST CANCER 8P12 P11 AMPLICON c2.REACTOME ENERGY DEPENDENT REGULATION OF MTOR BY LKB1 AMPK c2.REACTOME ENERGY DEPENDENT REGULATION OF MTOR BY LKB1 AMPK c2.REACTOME RNA POLYMERASE II TRANSCRIPTION c2.WP IRON METABOLISM IN PLACENTA c2.GARY CD5 TARGETS DN c2.MATZUK EARLY ANTRAL FOLLICLE c2.REACTOME INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS c2.REACTOME REGULATION OF HOMOTYPIC CELL CELL ADHESION c2.REACTOME REGULATION OF HOMOTYPIC CELL CELL ADHESION c2.REACTOME COLLAGEN FORMATION c2.ZHAN MULTIPLE MYELOMA CD1 AND CD2 DN c2.REACTOME SIGNALING BY LEPTIN c2.HOFFMAN CLOCK TARGETS UP c2.WP 10Q1121Q1123 COPY NUMBER VARIATION SYNDROME c2.WP ENDOPLASMIC RETICULUM STRESS RESPONSE IN CORONAVIRUS INFECTION					
c2.WP ENDOPLASMIC RETICULUM STRESS RESPONSE IN CORONAVIRUS INFECTION c2.REACTOME NOTCH3 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION c2.REACTOME ROS AND RNS PRODUCTION IN PHAGOCYTES c2.GRABARCZYK BCL11B TARGETS UP c2.REACTOME INTERFERON SIGNALING c2.GENTILE UV RESPONSE CLUSTER D2 c2.REACTOME INTERFERON SIGNALING c2.GENTILE UV RESPONSE CLUSTER D2 c2.REACTOME CHONDROITIN SULFATE BIOSYNTHESIS c2.REACTOME ACTIVATION OF RAC1 c2.LIU COMMON CANCER GENES c2.REACTOME ACTIVATION OF RAC1 c2.LIU COMMON CANCER GENES c2.REACTOME TRANSCRIPTIONAL REGULATION OF GRANULOPOIESIS c2.REACTOME RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES c2.WP NOTCH1 REGULATION OF ENDOTHELIAL CELL CALCIFICATION c2.REACTOME BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN GENE EXPRESSION c2.GINESTIER BREAST CANCER 20Q13 AMPLIFICATION DN c2.REACTOME BREAST CANCER 20Q13 AMPLIFICATION DN c2.KEGG MEDICUS PATHOGEN EBV BANACT TO BCL2 INHIBITOR UP					
c2.KEGG MEDICUS PATHOGEN EBV EBNA3C TO CELL CYCLE G1 S N00483 c2.KEGG MEDICUS REFERENCE P16 CELL CYCLE G1 S c2.LASTOWSKA NEUROBLASTOMA COPY NUMBER DN c2.PID TCR JNK PATHWAY c2.REACTOME RNA POLYMERASE I PROMOTER ESCAPE c2.REACTOME PIN METABOLISM c2.HASLINGER B CLL WITH CHROMOSOME 12 TRISOMY c2.REACTOME MITF M REGULATED MELANOCYTE DEVELOPMENT c2.BOYAULT LIVER CANCER SUBCLASS G1 DN c2.CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS CDC25 DN c2.MOROSETTI FACIOSCAPULOHUMERAL MUSCULAR DISTROPHY UP c2.SINGH NFE2L2 TARGETS c2.REACTOME NEDDYLATION c2.KEGG MEDICUS PATHOGEN EBV BARF1 TO INTRINSIC APOPTOTIC PATHWAY c2.LEE METASTASIS AND ALTERNATIVE SPLICING UP c2.ZHENG FOXP3 TARGETS IN THYMUS UP c2.THUM SYSTOLIC HEART FAILURE DN c2.KEGG MEDICUS REFERENCE ITGA B FAK CDC42 SIGNALING PATHWAY c2.BANDRES RESPONSE TO CARMUSTIN WITHOUT MGMT 48HR DN					
c2.BANDRES RESPONSE TO CARMUSTIN WITHOUT MGMT 48HR DN c2.JEON SMAD6 TARGETS UP c2.ONDER CDH1 TARGETS 2 UP c2.REACTOME GABA SYNTHESIS RELEASE REUPTAKE AND DEGRADATION c2.REACTOME RESOLUTION OF SISTER CHROMATID COHESION c2.REACTOME RUNX2 REGULATES OSTEOBLAST DIFFERENTIATION c2.BIOCARTA CHEMICAL PATHWAY c2.BIOCARTA P38MAPK PATHWAY c2.KEGG MEDICUS REFERENCE EGF EGFR RAS RASSF1 SIGNALING PATHWAY c2.WP KENNEDY PATHWAY FROM SPHINGOLIPIDS	0.2 0.0 0.2 0.4			0.2 0.0 0.2 0.4	